Clinical Core

临床核心

• 批准号: 10413831
• 负责人: DAVID S KNOPMAN
• 金额: $ 72.06万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-07-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10413831
• 关键词: African American population; Alzheimer' s Disease; Amyloid; Autopsy; Basic Science; Biological Markers; Blood; Cerebrospinal Fluid; Clinic; Clinical; Cognition Disorders; Correlation Studies; DNA; Data; Databases; Diagnosis; Diagnostic; Disease; Elderly; Etiology; Evaluation; Foundations; Frontotemporal Lobar Degenerations; Funding; Genetic; Goals; Grant; Guidelines; Hallucinations; Image; Impaired cognition; Individual; Interview; Judgment; Lewy Bodies; Lewy Body Disease; Life; Liquid substance; Modeling; Multimodal Imaging; Natural History; Neurodegenerative Disorders; Neurologist; Parkinsonian Disorders; Participant; Pathologic; Pathology; Patients; Persons; Positron-Emission Tomography; Procedures; Recording of previous events; Research; Research Personnel; Scheme; Science; Sea; Series; Services; Severities; Sleep; Standardization; Syndrome; Technology; United States National Institutes of Health; base; biomarker evaluation; clinical diagnosis; clinical diagnostics; cognitive testing; diagnostic accuracy; diagnostic criteria; imaging biomarker; improved; informant; interest; neuroimaging; neuropathology; programs; recruit; specific biomarkers; synergism; tau Proteins

PROJECT DESCRIPTION/ABSTRACT – CLINICAL CORE The Clinical Core will serve as the focal point of the Mayo ADRC. The Clinical Core of the Mayo ADRC has been among the leaders among Alzheimer's Disease Centers in recruiting and retaining participants. The Mayo ADRC has focused and will continue to focus on imaging in the Alzheimer spectrum (AD), the genetics, imaging and natural history of Frontotemporal Lobar Degeneration (FTLD) group of disorders and the imaging, associated features (sleep, Parkinsonism, hallucinations, etc) and natural history of Lewy Body disorders (LBD) spectrum (FTLD and LDB collectively the Alzheimer's disease related disorders “ADRD”). For each of these etiologic entities, Mayo investigators hold NIH grants, in part due to the ADRC that utilize the ADRC participant pool. Over the last cycle of funding, we have greatly expanded the number of participants, including African Americans, who have undergone amyloid PET imaging. Moreover in the last grant cycle, we introduced tau PET imaging as well in the MCR group, and we will do so soon in MCF. There are many synergies that arise from our concurrent interest in AD and ADRD both for clinical characterization, but also for biomarker evaluations, and basic science commonalities. The Clinical Core diagnostic and evaluative activities will take place in both MCR and MCF, and the data derived from the evaluation schemes are entered into a single database. The core procedures of the UDS3 are carried out according to NACC guidelines, and additional evaluations specific to our programs are also conducted. All patients and controls undergo a standardized series of interviews, examinations and biomarkers studies over 2-3 days. All participants are seen by a neuropsychologist and neurologist. Our Specific Aims are to (1) Recruit, follow and supply to other projects, patients with AD spectrum disorders; (2) Recruit, follow and supply to other projects patients, in the ADRD spectrum; (3) Recruit African-Americans with above disorders (collaborating with ORE Core); (4) Obtain DNA, blood, cerebrospinal fluid (collaborating with Biomarker Core) and multimodal imaging (Collaborating with Neuroimaging Core) on participants; and (5) Obtain autopsies on Clinical Core participants (collaborating with Neuropathology Core).

项目说明/摘要-临床核心 临床核心中心将作为梅奥ADRC的焦点。梅奥ADRC的临床核心 在招募和留住参与者方面一直是阿尔茨海默病中心的领导者之一。这个 梅奥ADRC已经并将继续专注于阿尔茨海默氏谱(AD)的成像，遗传学， 额颞叶退行性变(FTLD)组的影像和自然病史及其影像， 路易体病的相关特征(睡眠、帕金森症、幻觉等)和自然病史 (LBD)谱(FTLD和LDB统称为阿尔茨海默病相关疾病“ADRD”)。对于每一个 这些病因学实体，梅奥调查人员持有NIH拨款，部分原因是ADRC利用ADRC 参与者池。在上一个筹资周期中，我们大大扩大了参与者的数量， 包括非裔美国人，他们接受了淀粉样蛋白PET成像。此外，在上一个赠款周期中，我们 在MCR组中也引入了tau PET成像，我们很快就会在MCF中这样做。有很多 由于我们同时对AD和ADRD感兴趣而产生的协同效应，不仅适用于临床特征，也适用于 生物标记物评估和基础科学共性。临床核心诊断和评估活动 将在MCR和MCF中进行，从评估方案中获得的数据被输入到 单一数据库。UDS 3的核心程序是根据NACC指南执行的，以及 我们还进行了针对我们计划的其他评估。所有患者和对照组都要接受 为期2-3天的标准化系列访谈、考试和生物标志物研究。所有参与者都是 由一位神经心理学家和神经科医生看过。我们的具体目标是(1)招聘、跟踪和供应给其他人 项目，AD谱系障碍患者；(2)招募、跟踪和供应其他项目的患者，在 ADRD谱；(3)招募有上述障碍的非裔美国人(与ORE Core合作)；(4) 获取DNA、血液、脑脊液(与Biomarker Core合作)和多模式成像 (与神经成像核心合作)参与者；以及(5)获取临床核心参与者的尸检 (与神经病理核心合作)。